logo
This Turnaround Stock Has Tripled from Its 52-Week Lows: Is It Still a Buy?

This Turnaround Stock Has Tripled from Its 52-Week Lows: Is It Still a Buy?

Yahoo3 hours ago
While corporate turnarounds are somewhat of a cliche, there are genuine turnaround stories to be found. One of them is fitness equipment and subscription company Peloton (PTON), which, like other pandemic-era winners, had to reboot its business strategy.
While the stock trades at a tiny fraction of its all-time highs, it has more than tripled from its 52-week lows that it hit last year. In this article, we'll examine whether there's still heat left in PTON's rally that has helped it recoup its 2025 losses and nearly turn positive for the year.
More News from Barchart
Why This Cannabis Penny Stock Could Be Wall Street's Next Meme Trade Breakout
Apple Stock Is Gaining Momentum, Is AAPL Stock a Buy?
Peter Thiel-Backed Bullish Is About to IPO. Should You Buy BLSH Stock?
Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines.
Peloton Is a Turnaround Play
To begin with, let's look at the progress in Peloton's turnaround, which began in February 2022 when Barry McCarthy – the former Netflix (NFLX) and Spotify (SPOT) executive – took over as CEO, replacing the company's co-founder, John Foley. He embarked on an aggressive cost-cutting program, including through layoffs, and Peloton pivoted to third-party production to reduce fixed costs.
While these measures help Peloton trim losses and turn free cash flow positive, PTON shares continued to dwindle and fell to record lows last year. In October 2024, Peloton announced Apple Fitness+ (AAPL) co-founder Peter Stern as its next CEO. Stern took over in early 2025 and is now leading the next leg of Peloton's turnaround, which includes turning around the corner on top-line growth.
PTON's Revenues Have Fallen
Peloton's revenues have fallen for four consecutive years, and its sales in fiscal 2025, which ended in June, were just about 62% of fiscal year 2021 levels. The midpoint of its guidance implies a 2% year-over-year fall in this year's revenues, also. There is, however, a silver lining here as the top end of the guidance implies a yearly rise in revenues. Also, even the midpoint of the guidance implies some growth in the final three quarters of this fiscal year, as the company expects revenues to fall 9% at the midpoint in the current quarter.
Peloton has taken several measures to boost its sales. These include promotional pricing for different groups, the launch of micro stores to improve brand visibility, and the launch of Peloton Repowered, its platform for buying and selling used equipment.
Peloton Has Turned Free Cash Flow Positive
One of the concerns for Peloton investors was the company's losses and cash burn. PTON has been working on aggressive cost cuts, and after achieving run-rate savings of $200 million in fiscal 2025, it is targeting another $100 million worth of savings in the current fiscal year.
In FY 2025 it generated healthy free cash flows of $323.7 million, which were ahead of its guidance. The company expects net working capital and restructuring charges to be a headwind for its free cash flows this year, while forecasting a tariff impact of $65 million. Despite these challenges, it has forecast free cash flows above $200 million this year, which is quite encouraging.
Peloton has been using its free cash flows to pare its debt and ended June with net debt of $459 million, 43% lower than the corresponding period last year. As Peloton's balance sheet continues to improve and interest rates come down, the company should be able to refinance its debt at much better terms than what they are currently.
Peloton Stock Forecast
Analysts have gradually turned bullish on Peloton as the company has shown impressive progress in its turnaround. Over the last two weeks only, UBS and Goldman Sachs have upgraded the stock from a 'Neutral' to 'Buy.'
Of the 20 analysts rating PTON, 10 each rate it as a 'Moderate Buy' and 'Hold' while its mean target price of $10.39 is 19% higher than the Aug. 13 closing price.
Peloton stock trades at a forward price-sales multiple of 1.45x while the enterprise value-to-earnings before interest, tax, depreciation, and amortization (EV-to-EBITDA) multiple is 10.4x. The multiples are not too demanding considering the current mix of Peloton's business, where around two-thirds of its revenues come from subscriptions, with volatile product sales accounting for the rest.
I believe there is still heat left in Peloton's rally as it strives to become a broad-based wellness partner for its members, including mental well-being, sleep, and nutrition. The turnaround has been going at a steady pace, and the stock could reward shareholders even further if the company can return to top-line growth while continuing to improve its margins and cash flows.
On the date of publication, Mohit Oberoi had a position in: PTON, AAPL, NFLX. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi
Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi

Yahoo

time20 minutes ago

  • Yahoo

Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi

We recently published . Hudbay Minerals Inc. (NYSE:HBM) is one of the best-performing stocks on Wednesday. Hudbay Minerals grew its share prices for a second day on Wednesday, up 15.03 percent to close at $11.33 apiece, following an impressive earnings performance and a $600-million investment from Mitsubishi Corp. In its updated report, Hudbay Minerals Inc. (NYSE:HBM) said it swung to a net income attributable to shareholders of $117.7 million from an attributable net loss of $16.5 million in the same period last year, driven by higher gross margins and strong cost control. Revenues increased by 26 percent to $536.4 million from $425.5 million year-on-year. 'With the strong performance in the first half of the year, we are reaffirming our full year consolidated production guidance and are favourably tracking well below our full year consolidated cost guidance for 2025,' said Hudbay Minerals Inc. (NYSE:HBM) President and CEO Peter Kukielski. For the full-year period, the company is targeting to produce between 117,000 and 149,000 tons of copper, as well as 247,500 to 308,000 ounces of gold. In other news, Hudbay Minerals Inc. (NYSE:HBM) was able to raise $600 million in fresh funds from Mitsubishi Corp. after the latter acquired a 30-percent stake in Copper World LLC. Under the agreement, Mitsubishi will pay an upfront cash of $420 million, with the balance to serve as a matching contribution within an 18-month period. While we acknowledge the potential of HBM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?
Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?

Yahoo

time20 minutes ago

  • Yahoo

Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?

We recently published . Paramount Skydance Corp. (NASDAQ:PSKY) is one of the best-performing stocks on Wednesday. Paramount Skydance extended its rally to touch a new high on Wednesday, finishing up by 36.74 percent at $15 apiece, with a former hedge fund manager calling it a 'meme' stock. In a social media post, Mad Money host and former hedge fund manager Jim Cramer said Paramount Skydance Corp. (NASDAQ:PSKY) is a 'meme stock' given the company's small public float and unjustifiable rally amid the lack of fresh developments. Paramount Skydance Corp. (NASDAQ:PSKY) climbed by as high as 60 percent at intra-day trading to hit $17.53 before paring gains to finish slightly lower during the session. In recent news, the company bagged a new $7.7-billion deal to exclusively air the Ultimate Fighting Championship (UFC) on Paramount+ for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. cellanr, CC BY-SA 2.0 , via Wikimedia Commons As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will move UFC away from the existing Pay-Per-View model and make the latter available at no additional cost to Paramount+ subscribers in the US. It also intends to explore UFC rights outside the US in the future. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results

Yahoo

time20 minutes ago

  • Yahoo

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results

We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store